Diabetes is commonly associated with depression and the two result from common biological factors, such as chronic inflammation, disturbed hypothalamic-pituitary-adrenal axis, insulin resistance and circadian dysrhythmia. Behavioral abnormalities associated with depression frequently contribute to poor lifestyle adherence and medication use. Additionally, since depression and diabetes overlap in their presentation, diagnosis of depression must be refined to distinguish it from symptoms of diabetes. Depression in diabetes must therefore be identified and the two simultaneously managed. One must scale up access to resources in order to achieve this.
As part of our journal’s mission to address strategies and interventions to help individuals with diabetes to achieve optimal physical and mental health outcomes, Frontiers in Clinical Diabetes and Healthcare is organizing this research topic focused on ‘Depression and Diabetes’.
Original research or systematic reviews including but not limited to the following areas are therefore encouraged:
• Epidemiology of recent studies, including meta-analyses and scoping reviews of depression and diabetes
• Differentiating depression from diabetes distress, subclinical depression and anxiety
• Psychometric properties of instruments to identify depression in diabetes
• Biomarkers to differentiate endogenous depression from depression in diabetes, including biochemistry, genetics and metabolomics
• Critical analysis of the recent pathobiological basis for the co-existence of depression and diabetes
• The economic impact of depression and diabetes
• Adverse metabolic effects of antidepressant medications
• The choice of antidepressant drugs for patients with diabetes
• Critical analysis of results of therapy on the outcomes of depression and metabolic control
• Outcomes of psychological methods, including cognitive behavior therapy and mindfulness in depression and diabetes
• Methods to improve metabolic outcomes along with depressive symptoms
• Public health measures to improving access to treatment for depression and diabetes, including coordinated care
• Preventive measures that are common to both depression and diabetes: a focus on physical exercise, built environment, and circadian rhythm including sleep
• Newer potential pharmacological agents, such as exercise mimetics, in treating depression and diabetes
Diabetes is commonly associated with depression and the two result from common biological factors, such as chronic inflammation, disturbed hypothalamic-pituitary-adrenal axis, insulin resistance and circadian dysrhythmia. Behavioral abnormalities associated with depression frequently contribute to poor lifestyle adherence and medication use. Additionally, since depression and diabetes overlap in their presentation, diagnosis of depression must be refined to distinguish it from symptoms of diabetes. Depression in diabetes must therefore be identified and the two simultaneously managed. One must scale up access to resources in order to achieve this.
As part of our journal’s mission to address strategies and interventions to help individuals with diabetes to achieve optimal physical and mental health outcomes, Frontiers in Clinical Diabetes and Healthcare is organizing this research topic focused on ‘Depression and Diabetes’.
Original research or systematic reviews including but not limited to the following areas are therefore encouraged:
• Epidemiology of recent studies, including meta-analyses and scoping reviews of depression and diabetes
• Differentiating depression from diabetes distress, subclinical depression and anxiety
• Psychometric properties of instruments to identify depression in diabetes
• Biomarkers to differentiate endogenous depression from depression in diabetes, including biochemistry, genetics and metabolomics
• Critical analysis of the recent pathobiological basis for the co-existence of depression and diabetes
• The economic impact of depression and diabetes
• Adverse metabolic effects of antidepressant medications
• The choice of antidepressant drugs for patients with diabetes
• Critical analysis of results of therapy on the outcomes of depression and metabolic control
• Outcomes of psychological methods, including cognitive behavior therapy and mindfulness in depression and diabetes
• Methods to improve metabolic outcomes along with depressive symptoms
• Public health measures to improving access to treatment for depression and diabetes, including coordinated care
• Preventive measures that are common to both depression and diabetes: a focus on physical exercise, built environment, and circadian rhythm including sleep
• Newer potential pharmacological agents, such as exercise mimetics, in treating depression and diabetes